Filing Details

Accession Number:
0001628280-19-010686
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-08-13 16:33:57
Reporting Period:
2019-08-09
Accepted Time:
2019-08-13 16:33:57
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1576280 Guardant Health Inc. GH Services-Medical Laboratories (8071) 454139254
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1721003 B. Richard Lanman 505 Penobscot Drive
Redwood City CA 94063
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-08-09 2,307 $4.18 141,632 No 4 M Direct
Common Stock Acquisiton 2019-08-09 3,458 $8.80 145,090 No 4 M Direct
Common Stock Disposition 2019-08-09 11,399 $103.79 133,691 No 4 S Direct
Common Stock Disposition 2019-08-09 16,060 $104.80 117,631 No 4 S Direct
Common Stock Disposition 2019-08-09 25,520 $105.69 92,111 No 4 S Direct
Common Stock Disposition 2019-08-09 9,596 $106.47 82,515 No 4 S Direct
Common Stock Disposition 2019-08-09 500 $107.18 82,015 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock STOCK OPTION (RIGHT TO BUY) Disposition 2019-08-09 2,307 $0.00 2,307 $4.18
Common Stock STOCK OPTION (RIGHT TO BUY) Disposition 2019-08-09 3,458 $0.00 3,458 $8.80
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
15,371 2027-05-30 No 4 M Direct
42,655 2028-08-21 No 4 M Direct
Footnotes
  1. These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Some of the shares sold were acquired contemporaneously upon the cashless exercise of one or more stock options at an exercise price of $4.18 or $8.80 per share.
  2. The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $103.10 to $104.08. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
  3. The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $104.11 to $105.10. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
  4. The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $105.11 to $106.10. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
  5. The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $106.11 to $107.02. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
  6. The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 1, 2017.
  7. The expiration date of May 31, 2027 reported in the Reporting Person's prior Form 4 filings was in error.
  8. The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on August 22, 2018.
  9. The expiration date of August 22, 2028 reported in the Reporting Person's prior Form 4 filings was in error.